Takeda’s Narcolepsy Drug Candidate Clears Phase 3 | Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review
At CHEST, the company released additional data from its pivotal phase 3 SynAIRgy and LunAIRo trials evaluating the investigational drug, AD109.| Sleep Review
The $2.1 billion all-cash deal will bring Avadel’s once-nightly oxybate, LUMRYZ, under Alkermes’ umbrella as it advances its orexin agonist pipeline for narcolepsy and other hypersomnolence disorders.| Sleep Review
Mineralys Therapeutics’ lorundrostat targets nocturnal hypertension linked to sleep apnea.| Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review
